Business Bites: Spectranetics and Volcano go shopping
This article was originally published in Clinica
Executive Summary
Two cardiovascular device companies have made their first acquisitions of 2014: Spectranetics has agreed to buy balloon developer AngioScore for $230m upfront; while Volcano has inked a deal for peripheral arterial disease specialist AtheroMed for $115m plus milestones.